NCT01651104View on ClinicalTrials.gov

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Human Influenza
Interventions
BIOLOGICAL

Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)

A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.

Trial Locations (1)

185

University Hospital Ghent Center for Vaccinology, De Pintelaan

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY